Guidance

Pneumococcal polysaccharide conjugate vaccine (PCV20) PGD template

Patient group direction (PGD) template to support the provision of pneumococcal polysaccharide conjugate vaccine (PCV20).

• From: UK Health Security Agency
• Published: 17 December 2025
• Last updated: 3 August 2026 — See all updates

Applies to England

Documents

PCV20 PGD template

MS Word Document, 137 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The PCV20 PGD version 2 has been updated to include people experiencing homelessness (PEH) as a new clinical risk group eligible for pneumococcal vaccination from 1 October 2026.

This PGD template supports the provision of 20-valent pneumococcal polysaccharide conjugate vaccine (PCV20) to the following cohorts:

• adults aged 65 years and over (as replacement for 23-valent pneumococcal polysaccharide vaccine (PPV23))
• individuals experiencing homelessness who are rough sleepers and those using hostels for the  homeless or night shelters
• individuals from 2 years of age in a clinical risk group (as replacement for PPV23)
• individuals under 2 years of age with asplenia, splenic dysfunction, complement disorder or severe immunocompromise (as replacement for 13-valent pneumococcal conjugate vaccine (PCV13) or 15-valent pneumococcal conjugate vaccine (PCV15))
• public health management of clusters of severe pneumococcal disease in closed settings in accordance with the UK guidelines (as replacement for PCV13 or PCV15)

Please also refer to the following letter:

Change of vaccine for the routine adult pneumococcal vaccination programme and individuals at increased clinical risk letter.

The PCV20 version 2.0 PGD is valid from 29 April 2026 to 29 April 2029.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement see Human Medicines Regulations 2012. Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics.

Published 17 December 2025

Last updated 3 August 2026 — Show all updates

1. 3 August 2026

   Added version 2 - see page 3 for change history.

2. 17 December 2025

   First published.